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Abstract
Chronic hepatitis B (CHB) infection is a major public 
health problem associated with significant morbid-
ity and mortality worldwide. Twenty-three percent of 
patients with CHB progress naturally to liver cirrhosis, 
which was earlier thought to be irreversible. However, 
it is now known that cirrhosis can in fact be reversed by 
treatment with oral anti-nucleotide drugs. Thus, early 
and accurate diagnosis of cirrhosis is important to allow 
an appropriate treatment strategy to be chosen and to 
predict the prognosis of patients with CHB. Liver biopsy 
is the reference standard for assessment of liver fibro-
sis. However, the method is invasive, and is associated 
with pain and complications that can be fatal. In addi-
tion, intra- and inter-observer variability compromises 
the accuracy of liver biopsy data. Only small tissue 
samples are obtained and fibrosis is heterogeneous in 
such samples. This confounds the two types of observ-
er variability mentioned above. Such limitations have 
encouraged development of non-invasive methods for 
assessment of fibrosis. These include measurements 
of serum biomarkers of fibrosis; and assessment of 
liver stiffness via  transient elastography, acoustic radia-
tion force impulse imaging, real-time elastography, or 
magnetic resonance elastography. Although significant 
advances have been made, most work to date has ad-
dressed the diagnostic utility of these techniques in 
the context of cirrhosis caused by chronic hepatitis C 
infection. In the present review, we examine the ad-
vantages afforded by use of non-invasive methods to 
diagnose cirrhosis in patients with CHB infections and 
the utility of such methods in clinical practice. 
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Chronic hepatitis B (CHB) infection is associ-
ated with significant morbidity and mortality because it 
can progress to cirrhosis or hepatocellular carcinoma. 
Early diagnosis of liver cirrhosis in CHB patients is 
important to prevent the disease progression. Non-
invasive diagnosis has been developed remarkably and 
showed high diagnostic accuracy for cirrhosis. New 
methods and the combination of non-invasive diagnosis 
tools may contribute to the improvement to diagnose 
the cirrhosis with CHB.
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INTRODUCTION
Serologically, hundreds of  millions of  people are chronic 
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hepatitis B (CHB) virus surface antigen (HBsAg) carri-
ers and it is estimated that over 200000 CHB patients die 
worldwide each year from cirrhosis[1,2]. The prognosis 
is worse in those infected by hepatitis B virus (HBV) in 
areas in which the virus is endemic. The annual rate of  
progression from chronic hepatitis to cirrhosis is 2%-5% 
in HBV e antigen-positive and 3%-10% in e antigen-
negative patients[3].
Early diagnosis of  liver cirrhosis in CHB patients 
is important because cirrhosis per se is an independent 
predictor of  mortality. The 1-year mortality rates vary 
from 1% in patients with early-stage cirrhosis to 57% in 
those with decompensated disease[4-6]. In addition, the 
5-year cumulative risk that a cirrhotic patient will develop 
hepatocellular carcinoma is 10%-17%[3]. Diagnosis of  
cirrhosis in CHB patients may trigger early initiation of  
antiviral treatment, which improves clinical outcomes. 
Also, development of  complications in such patients is 
monitored regularly[7,8].
Traditionally, cirrhosis has been diagnosed with the 
aid of  clinical information, including laboratory and im-
aging data. However, such methods have their limitations, 
and a liver biopsy has usually been required to confirm a 
diagnosis of  liver cirrhosis.
Cirrhosis occurs in response to chronic liver injury 
and constitutes the final stage of  progressive hepatic fi-
brosis characterized by distortion of  hepatic architecture 
and formation of  regenerative nodules[9]. If  a liver biopsy 
sample is to be adequately diagnostic, the sample should 
be at least 2-3 cm in length and contain more than 11 
complete portal tracts[10]. However, it is usually difficult to 
fulfill these requirements. Also, the evaluation of  simulta-
neous biopsies taken from the left and right lobes yielded 
different fibrosis scores in 33% of  patients[11]. Intra- and 
inter-observer variation contribute to test variability[12]. 
Biopsy is associated with a bleeding risk of  1%[13] and a 
mortality rate of  approximately 0.01%[14].
Therefore, it is necessary to investigate the new diag-
nostic methods for improving the limitations and compli-
cations of  liver biopsy. Non-invasive modalities, includ-
ing transient elastography (TE), acoustic radiation force 
impulse imaging (ARFI), real-time elastography (RTE), 
and magnetic resonance elastography (MRE), have been 
developed to overcome the problems discussed above. 
Also, markers of  cirrhosis have been sought in blood. 
Such non-invasive modalities have attracted much at-
tention[15-22]. In the present review, we examine the roles 
played by non-invasive diagnostic modalities in terms of  
assessment of  cirrhosis and prediction of  the prognosis 
of  CHB patients.
CLASSICAL DIAGNOSIS OF LIVER 
CIRRHOSIS USING CLINICAL 
INFORMATION
Clinicians usually take a clinical history, conduct a physi-
cal examination, and review laboratory and imaging data 
to diagnose liver cirrhosis in CHB patients.
First, history-taking is a basic clinical approach. For 
example, a family or past history of  HBV infection is an 
important clue to decide whether cirrhosis may or may 
not be caused by HBV. The histories of  blood transfu-
sion, needle injury, and sexual activity are important fac-
tors for the route of  infection. 
Second, physical examination is both simple and es-
sential. Spider angioma, splenomegaly, hepatomegaly, a 
distended abdomen, the presence of  shifting fluid, and 
pitting edema suggestive of  portal hypertension, all aid 
in the diagnosis of  liver cirrhosis in CHB patients. Blood 
samples should be evaluated for the presence of  HBV 
surface antigen, platelet count, albumin level, prothrom-
bin time, and total bilirubin concentration. Simple blood 
test data do not afford great sensitivity in diagnosis of  
cirrhosis, but one meta-analysis found that the presence 
of  ascites [likelihood ratio (LR) = 7.2], a platelet count < 
160000/mm3 (LR = 6.3), and spider nevi (LR = 4.3) were 
all usefully predictive of  cirrhosis[23]. These simple blood 
tests, and data from physical examination, are necessary 
to evaluate the severity of  cirrhosis, being parameters 
used to derive Child-Pugh or Model for End-Stage Liver 
Disease (MELD) scores for cirrhotic patients.
Third, imaging modalities including ultrasound, ab-
dominal computed tomography (CT), and magnetic reso-
nance imaging (MRI), can aid in detection of  cirrhosis or 
hepatocellular carcinoma in HBV patients. Liver cirrhosis 
is typically associated with splenomegaly, hepatomegaly, 
a coarse echo pattern of  the liver parenchyma, nodularity 
of  the liver surface, a blunt angle, ascites, and thrombus 
of  the portal vein[24-27]. The sensitivity, specificity, posi-
tive predictive value (PPV), negative predictive value 
(NPV), and accuracy of  ultrasound used to predict the 
presence of  HBV-related cirrhosis were 77.8%, 92.5%, 
87.5%, 86.0%, and 86.6%, respectively, and were higher 
in CHB patients than in those with chronic hepatitis C 
(CHC)[27]. Such radiological findings are also important 
when abdominal CT or MRI is used to diagnose liver cir-
rhosis. Additionally, other radiological findings including 
the velocity of  portal flow, the shape of  the hepatic vein 
waveform (as revealed by Doppler testing), and the cau-
date lobe/right lobe ratio with use of  the main or right 
portal vein to set the lateral boundary (as revealed on CT 
or MRI), are useful[24,28-30]. Of  these parameters, a caudate 
lobe/right lobe ratio over 0.65 is suggestive of  the pres-
ence of  liver cirrhosis. The sensitivity, specificity, and 
accuracy of  this measure were 84%, 100%, and 94%, re-
spectively[30]. Liver surface nodularity, a platelet count less 
than 100000/mm3, an albumin level less than 3.5 g/dL, 
and an international normalized prothrombin time ratio 
of  1.3 or more, are also associated with liver cirrhosis. 
Each of  these findings is associated with a specificity and 
sensitivity of  90% and 61%, respectively, in terms of  cir-
rhosis diagnosis[31].
An overview of  clinical history, physical examination, 
and review of  laboratory and imaging test data, combine 
to aid in the diagnosis of  HBV-caused cirrhosis. The use 
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of  clinical strategies that combine elements of  these diag-
nostic modalities is crucial to diagnose cirrhosis in CHB 
patients and to plan suitable treatment. 
TRANSIENT ELASTOGRAPHY
Measurement of liver stiffness
TE is a representative noninvasive method used to di-
agnose cirrhosis or assess the extent of  fibrosis using 
ultrasound elastography. The propagation velocity of  
transient shear waves of  low amplitude and frequency (50 
Hz) is affected by the elasticity of  the liver parenchyma. 
If  the waves propagate rapidly, the fibrotic burden is 
large[32]. The outcome is expressed as a pressure (thus in 
kilopascals; kPa) and ranges from 2.5 to 75 kPa (normal, 
5 kPa)[33-35]. The reliability of  the technique has been re-
ported to be over 60% and the median interquartile range 
less than 30%[36-38]. The generator is placed over an in-
terspace of  the ribcage of  the right upper quadrant. The 
test usually takes 5-10 min. Typically, 10 or more mea-
surements are taken but three valid measurements suffice 
to reliably diagnose liver fibrosis in CHB patients[39].
Diagnostic performance
Most studies have found that TE performs well when 
used to diagnose and measure the extent of  liver fibrosis 
in patients with CHC infection or other liver condi-
tions[40-42]. TE also afforded acceptable diagnostic accu-
racy in CHB patients[18-20]. Marcellin et al[20] reported that 
TE used to diagnose cirrhosis in CHB patients had a di-
agnostic accuracy of  94%, a sensitivity of  57%, a specific-
ity of  97%, a PPV of  67%, and an NPV of  96%. When 
maximal sensitivity and specificity are required, the cutoff  
value falls to 11.0 kPa (sensitivity 93%, specificity 87%, 
PPV 38%, and NPV 99%). Chan et al[19] found that TE 
yielded a good diagnostic performance in clinical practice. 
The maximal diagnostic accuracy was associated with a 
cutoff  of  13.4 kPa but this value was 12.0 kPa when the 
sum of  sensitivity and specificity was maximized. A liver 
stiffness measurement (LSM) cutoff  value can easily be 
determined for each particular clinical requirement. A 
highly sensitive cutoff  is useful when screening for early-
stage cirrhosis whereas a highly specific cutoff  would aid 
in detection of  significant fibrosis or cirrhosis. A cutoff  
affording a high diagnostic accuracy would be valuable 
to ensure correct diagnosis. Interestingly, the cutoffs 
obtained by maximizing the sum of  sensitivity and speci-
ficity, the area under the receiver operating characteristic 
(AUROC) curve, and diagnostic accuracy, were slightly 
lower for CHB than CHC patients. This is because the 
extent of  fibrosis is slightly less in the former patients[43]. 
Cirrhosis in CHB patients is more macronodular in na-
ture than in patients with CHC or alcoholic liver disease.
Kim et al[44] found that LSMs and biopsy data were 
not in agreement with measures of  necro-inflammatory 
activity in CHB patients. LSMs were significantly higher 
in cirrhotic patients in whom such activity was maximal 
(grades 3-4; grade 4 is termed F4) than when the activity 
was less (grades 1-2) (median of  19.2 kPa in the former 
patients vs 11.9 kPa in the latter; P = 0.009). The results 
of  liver biopsy and LSM differed in CHB patients with 
cirrhosis, principally when necro-inflammatory activity of  
grades 3-4 significantly increased the LSMs. 
In addition, serum levels of  aminotransferases must 
be considered when interpreting TE data from hepatitis 
B patients because alanine aminotransferase (ALT) flares 
(which are frequent in CHB patients) cause TE values 
to be artificially inflated[45]. Thus, patients with higher 
ALT levels tend to have greater LSMs than do those with 
lower ALT levels, even when the stage of  liver fibrosis 
is identical. Thus, TE values of  CHB patients should be 
interpreted cautiously because it is possible that patients 
with low-grade fibrosis may score as false-negatives 
whereas those with high ALT levels may yield false-
positive values. In patients with normal ALT levels, the 
optimal cutoff  values for reliable detection of  cirrhosis 
ranged from 8.4 to 12.0 kPa. However, in patients with 
elevated ALT levels [> 1-5-fold the upper limit of  nor-
mal (ULN)], the optimal cutoff  values ranged from 8.4 
to 13.4 kPa[19]. Kim et al[46] suggested that an appropriate 
LSM cutoff  value in CHB patients with ALT ≤ ULN 
was 10.1 kPa, but 15.5 in those with ALT > ULN and 
ALT < 2 × ULN. When only patients with ALT < ULN 
were studied, the cutoff  values allowing discrimination of  
each stage of  fibrosis were reduced, and the sum of  LSM 
sensitivity and specificity increased.
Both the total bilirubin level and the time of  perfor-
mance of  LSM have been explored in terms of  the abil-
ity to predict development of  cirrhosis in CHB patients. 
The total bilirubin level was significantly associated with 
changes in LSMs. However, the LSM was not reduced 
when measured soon after the levels of  ALT and total 
bilirubin normalized[47]. This suggests that normalization 
of  the LSM may occur only after laboratory measure-
ments on serum return to normal. Therefore, biochemi-
cal findings should be well-stabilized before LSMs can be 
considered reliable. 
LSM data did not differ when the detector was placed 
in the fifth, sixth, and seventh intercostal spaces[48]. All 
LSMs accurately predicted development of  cirrhosis. It 
was not necessary that the site of  LSM should corre-
spond to the liver biopsy site in cirrhotic HBV patients.
A meta-analysis of  50 studies found that the mean 
AUROC for reliable diagnosis of  significant fibrosis and 
cirrhosis was 0.94, with an optimal cutoff  LSM of  13.01 
kPa[49]. TE diagnosed severe fibrosis or cirrhosis more 
reliably than less advanced fibrotic stages. The data sug-
gest that TE is an excellent tool for use in clinical practice 
to confirm the presence of  cirrhosis when other clinical 
data are not definitive. 
Another meta-analysis of  the data of  nine studies 
showed that use of  TE to diagnose cirrhosis was as-
sociated with 87% sensitivity and 91% specificity[50]. TE 
affords good diagnostic accuracy when used to quantify 
the extent of  liver fibrosis in patients with either CHB or 
CHC. Chon et al[51] performed a meta-analysis of  18 stud-
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The probe is usually placed between the ribs on the 
right side (e.g., in segment 8) to reduce the effect of  car-
diac motion on measurement. Thus, the device is located 
approximately where a liver biopsy is usually performed 
1 cm under the capsule. Minimal scanning pressure is ap-
plied and the patient is asked to stop breathing for a mo-
ment, to minimize motion[62-64]. Data can also be obtained 
from the left lobe, which always appears to be stiffer than 
the right lobe, although data from both lobes correlate 
well with the stage of  fibrosis[65]. The difference in mea-
surement may be explained by variation in the pressure 
with which the ultrasonographic probe is placed. The 
probe is not directly applied to the right lobe because the 
chest wall intervenes to prevent direct probe contact with 
the liver.
Diagnostic performance
ARFI SWV diagnostic cutoff  values of  1.75-2.00 m/s 
have been reported in patients with liver cirrhosis[62-67]. 
Chen et al[68] explored the association between spleen stiff-
ness and advanced liver fibrosis. The optimal cutoff  value 
was 3.32 m/s for detection of  cirrhosis (80.0% sensitiv-
ity, 88.4% specificity, 55.5% PPV, 96.0% NPV). However, 
these data should be interpreted with caution because the 
proportion of  HBV patients in the tested population was 
too small to allow the diagnostic performance of  ARFI 
in cirrhotic HBV patients to be evaluated. ARFI has been 
used to examine patients with a variety of  liver diseases, 
principally hepatitis C infection. 
Friedrich-Rust et al[69] were the first to use ARFI to 
assess the severity of  liver fibrosis in HBV patients. In 
this prospective European multicenter study, the median 
SWV was 0.76-2.96 m/s in CHB patients. In terms of  
Metavir fibrosis scores, the median velocities were 1.10 
m/s for F0 patients, 1.14 m/s for F1 patients, 1.23 m/s 
for F2 patients, 1.60 m/s for F3 patients, and 1.75 m/s 
for F4 patients. The accuracy of  cirrhosis diagnosis was 
0.97. The cutoff  for diagnosis of  significant fibrosis (F 
grade ≥ 2) was 1.39 m/s with a sensitivity of  50%, a 
specificity of  90%, a PPV of  67%, an NPV of  73%, a 
positive likelihood ratio of  5.125, and a negative likeli-
hood ratio of  0.554. However, no optimal cutoff  for 
diagnosis of  cirrhosis in CHB patients was derived, be-
cause the number of  patients with F3/F4 fibrosis was 
too small. The diagnostic accuracy of  ARFI in HBV 
patients with different degrees of  fibrosis was lower than 
reported in previous studies on CHC patients who had 
fibrosis ranging from mild to significant, or cirrhosis. The 
accuracy of  ARFI when used to detect mild fibrosis was 
66% in HBV patients compared to 73% in studies on 
patients with CHC and other liver diseases. The accuracy 
values were 73% and 82%-90% in patients with signifi-
cant fibrosis, 94% and 90%-99% in those with severe 
fibrosis, and similar (97% and 87%-99%) in those with 
cirrhosis[62-72]. Further randomized prospective studies are 
required to determine whether ARFI data are influenced 
by underlying liver disease.
One meta-analysis reviewed 36 reports on ARFI im-
ies with 2772 patients and found that the cutoff  value 
for detection of  cirrhosis in Asian CHB patients was 
11.7 kPa, with a sensitivity and specificity of  84.6% and 
81.5%, respectively. The mean AUROC for diagnosis of  
cirrhosis was 0.929.
Advantages and disadvantages of TE
TE data are reproducible and the results have been vali-
dated in detail. The procedure time is less than 5 min. It 
is easy to evaluate patients either at the bedside or in the 
outpatient clinic. TE is useful when employed to follow-
up disease progression and to predict hepatic events pre-
ceding cirrhosis[52].
However, it is difficult to obtain TE data from obese 
patients [those with a body mass index (BMI) above 28 
kg/m2] and patients with narrow intercostal spaces, as-
cites, space-occupying tissue abnormalities, extrahepatic 
cholestasis, or congestion[15,53,54]. The difficulty of  reliably 
measuring liver stiffness in patients with ascites is a major 
disadvantage, because ascites is a typical sign of  cirrhosis.
Recently, an XL TE probe (as distinct from the stan-
dard M probe) has been used to gather data from obese 
patients. The XL probe afforded the best diagnostic per-
formance of  all probes tested and a relatively low level 
of  measurement failure[55]. Compared to the M probe, 
the XL probe operates at a lower frequency (3.5 MHz vs 
5 MHz), is longer (ultrasound transducer focal length of  
50 mm vs 35 mm), yields vibration of  greater amplitude 
(peak-to-peak 3 mm vs 2 mm), and has a greater depth of  
measurement (35-75 mm vs 25-65 mm). Failure of  LSM 
using the M probe occurred in 29.1% of  patients with 
BMIs of  30 kg/m2 or more, but the failure rate was only 
6.8% when the XL probe was employed.
Interestingly, eating prior to performance of  TE can 
compromise the accuracy of  LSMs in both CHC patients 
and those with other conditions[56,57]. The impact of  
ingestion on liver stiffness values is proportional to the 
stage of  fibrosis, being maximal in patients with cirrhosis. 
This is because liver stiffness increases as portal blood 
flow and the hepatic vein pressure gradient rise after a 
meal[58]. Therefore, it is necessary for a patient to fast for 
at least 2 h prior to performance of  TE. 
ACOUSTIC RADIATION FORCE IMPULSE 
IMAGING
Measurement of liver stiffness
ARFI, which employs conventional B-mode sonogra-
phy, is an alternative to TE. ARFI mechanically excites 
tissue for a brief  period via delivery of  a high-intensity 
acoustic pulse to a region of  interest (ROI). Shear waves 
propagate and generate localized tissue displacement[59]. 
The shear-wave velocity (SWV) is recorded in m/s and 
quantified in a region smaller than that examined when 
TE is employed (10 mm long and 6 mm wide). The ROI 
can be chosen by the operator. The SWV increases with 
stiffness. Thus, the SWV is an intrinsic and reproducible 
property of  tissue[59-61].
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aging of  CHB patients and those with other liver diseas-
es. In terms of  diagnosis of  patients of  F grade ≥ 3, the 
mean AUROCs of  studies including and excluding HBV 
patients were 0.87 (95%CI: 0.85-0.90) and 0.92 (95%CI: 
0.89-0.95), respectively[73]. Thus, AFRI afforded good di-
agnostic accuracy when used to detect cirrhosis.
Advantages and disadvantages
In contrast to TE, ARFI yields real-time information 
on the extent of  liver stiffness during observation using 
B-mode ultrasonography. Also, liver tissue can be directly 
targeted, with exclusion of  small non-parenchymatous 
areas (for example, blood vessels). If  a patient has a large 
right-side tumor or ascites, it is difficult to measure LSM 
using TE. In such instances, ARFI can be employed to 
diagnose cirrhosis. As ARFI is performed using a con-
ventional ultrasound instrument, ARFI and standard ul-
trasound examination may be performed using the same 
machine in the same session. This is convenient for CHB 
patients, who are usually examined ultrasonographically 
once or twice per year. 
The major disadvantage of  ARFI is that no long-term 
follow-up validation studies have been performed. Also, 
ARFI values, in contrast to TE values, have a narrow 
range (0.5-4.4 m/s). This makes it difficult to define pre-
cise cutoff  values that can be used to make decisions on 
patient management.
Cassinotto et al[55] reported that ARFI was (like TE) 
less efficient in obese patients. This is because the ultra-
sound beam travels poorly through thick fatty soft tissue. 
Thus, ARFI cannot be used as a first-line examination 
modality for obese patients.
An advantage of  ARFI is the ability to measure LSM 
in both the right and left lobes of  the liver. However, 
upon simultaneous liver biopsy of  both lobes, a between-
lobe difference of  at least one fibrosis stage was noted in 
only 33% of  patients, and liver cirrhosis was evident in 
only one biopsy in 14.5% of  cases[11].
Acute cellular infiltration, increased central venous 
pressure, and cholestasis, can cause the extent of  liver 
fibrosis to be overestimated. These possibilities should be 
considered when interpreting elastography data[74-76]. As 
is true of  TE measurements, food intake also increases 
ARFI-measured liver stiffness[77].
REAL-TIME ELASTOGRAPHY
Measurement of liver stiffness
RTE is a novel noninvasive ultrasound modality measur-
ing liver elasticity, and has recently been used to quan-
titatively assess the extent of  liver fibrosis[78-81]. As with 
ARFI, RTE uses a modified version of  standard ultra-
sound equipment. RTE propagates a shear wave through 
the liver and echo signals are captured in real time. 
Friedrich-Rust et al[79] and Kanamoto et al[82] examined the 
utility of  RTE in evaluation of  liver fibrosis. 
No special skills are required. A patient is placed in 
a supine position with the right arm extended above the 
head to stretch the intercostal muscles. After B-mode 
examination, the elastographic mode is selected. It is 
easy to verify the position of  the liver because the elas-
tographic images may be superimposed on B-mode 
reference images. The probe pressure may be varied 
manually. A small compression plate is usually attached to 
the ultrasonic probe so that stable tissue compression is 
attained and the stress field transmitted more uniformly. 
Tissue elasticity is color-coded (red: soft; blue: hard) in 
terms of  magnitude and superimposed on conventional 
two-dimensional (2D) images[83], allowing anatomical cor-
respondence to be noted. 
Diagnostic performance
Only a few reports on use of  RTE to evaluate CHB pa-
tients have appeared. Xie et al[84] used RTE to calculate 
elastic strain ratios (elastic strain values of  liver tissue in 
the ROI/strain values of  intercostal muscle in the ROI) 
in patients with different degrees of  liver fibrosis. The 
diagnostic cut-off  ratios were 1.10 in patients with sub-
stantial liver fibrosis and 0.60 in those with cirrhosis. The 
detection sensitivities for substantial fibrosis and cirrhosis 
were 77.8% and 50.0%, respectively, and the specifici-
ties 80.0% and 96.7%. The positive predictive values 
were 80.0% and 71.4% and the negative predictive values 
77.8% and 92.2%.
Wang et al[85] described the diagnostic performance of  
an elasticity index obtained using RTE, and the aspartate 
aminotransferase (AST) to platelet ratio index (APRI) 
used to stage liver fibrosis in CHB patients. The AU-
ROCs for detection of  cirrhosis were 0.66 and 0.23, re-
spectively. The diagnostic accuracies of  both tests used to 
assess the stage of  liver fibrosis (except cirrhosis) in CHB 
patients were high. In terms of  elasticity index distribu-
tion by Metavir fibrosis stage, the cut-off  value was 90.31 
for cirrhosis. 
Advantages and disadvantages
RTE reveals relative tissue strain in real time by measur-
ing tissue displacement. RTE can be used (as can ARFI) 
to evaluate liver fibrosis patients with ascites or who are 
severely obese. Eleven stiffness parameters are measured, 
and changes in tissue stiffness are thus evaluated system-
atically and sensitively. 
However, RTE requires further clinical validation. 
Although strain images are usually clear, artifacts include 
multiple reflections at the surface of  the liver; echo-free 
areas filled by thick blood vessels, ribs and lungs; and lack 
of  wave penetration. Also, if  the probe pressure is exces-
sive, the elastic relationship will vary (elasticity is nonlin-
ear). In addition, pressure is not uniformly transmitted to 
the liver because that tissue is slightly deformed by heart-
beats. However, good images can be obtained simply by 
applying the probe lightly to right-side intercostal regions. 
New quantitative analysis systems can measure tissue 
compression caused by the rhythmic beats of  the heart 
and blood vessels; no manual compression is required. 
This minimizes the capacity for human error.
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MAGNETIC RESONANCE 
ELASTOGRAPHY
Measurement of liver stiffness 
MRE is not yet widely available. The technique uses a 
modified phase-contrast method to image the propaga-
tive characteristics of  a shear wave traversing the liver[86]. 
A probe is placed against the patient’s back. Measure-
ments are obtained from the anterior segment of  the 
right lobe (the region of  the liver that is usually biopsied). 
Liver stiffness is measured by delineating an ROI of  at 
least 100 mm2 in the liver parenchyma, avoiding the edges 
of  the tissue, large vessels (> 3 mm in diameter), and fis-
sures. Low-frequency vibrations are emitted and the MRI 
spin echo sequence is used to gather data. Mean liver 
stiffness is expressed in kPa using a formula deriving a 
shear modulus, which is one-third the modulus of  Young 
used in TE evaluation[87]. 
Diagnostic performance
From a clinical viewpoint, MRE affords excellent accuracy 
when used to differentiate significant fibrosis from mild 
fibrosis or absence of  fibrosis, and cirrhosis from other 
stages of  liver fibrosis[88,89]. MRE has a high negative pre-
dictive value (97%) when used to exclude the presence of  
fibrosis[90]. A meta-analysis reviewing five studies employ-
ing MRE showed that the technique performed well diag-
nostically when used to evaluate liver cirrhosis attributable 
to different causes. The sensitivity of  the technique was 
92% and the specificity 96% when used differentiate F0-2 
fibrosis from fibrosis of  grades F3-4[91]. 
Venkatesh et al[92] found that MRE was an accurate 
non-invasive method when used to detect and stage fi-
brosis in CHB patients. The diagnostic performance of  
MRE was significantly higher than those of  serum fibro-
sis markers. The optimally discriminatory cutoff  MRE 
value was 4.33 kPA for diagnosis of  cirrhosis in CHB pa-
tients, with a sensitivity of  100%, a specificity of  100%, a 
PPV of  91.3%, and an NPV of  100%. Use of  MRE was 
associated with a 14.3% error rate. Therefore, MRE is a 
valuable non-invasive test when used to detect and stage 
liver fibrosis in CHB patients. 
Interestingly, the MRE cutoff  value for diagnosis of  
cirrhosis in CHB patients (4.33 kPa) was lower than that 
reported for CHC patients (6.20 kPa)[93] but similar to that 
associated with diagnosis of  advanced fibrosis in NASH 
patients (4.3 kPa)[94]. This suggests that the cutoff  values 
of  diagnostic MRE data differ for diseases that vary in 
etiology. However, such results require confirmation in 
large-scale studies. 
Advantages and disadvantages
MRE affords a significantly higher accuracy and techni-
cal success rate than other non-invasive modalities. MRE 
scans the entire liver and thus does not select an acoustic 
window. MRE can be used to evaluate obese patients or 
those with ascites. MRE can be easily incorporated into 
routine liver MRI; clinicians can simultaneously assess 
structural disease, liver stiffness, and fat and iron levels. 
Serum ALT level is a known confounding factor 
when fibrosis is detected using TE; liver stiffness is posi-
tively correlated with serum ALT levels[95,96]. However, 
MRE has exhibited no such association[89], probably be-
cause MRE and TE assess different mechanical proper-
ties.
However, MRE is quite expensive, and is not yet 
widely available. MRE cannot be used to evaluate patients 
who are claustrophobic or fitted with heart pacemakers. 
MRE is more time-consuming than are other ultrasound-
based elastographic methods. MRE cannot be performed 
on iron-overloaded livers because of  signal-to-noise limi-
tations.
SERUM BIOMARKERS
Measurement of liver stiffness
Diagnostic serum biomarkers of  liver fibrosis and cirrho-
sis have been well-validated. Although marker levels are 
highly reproducible, they are not specific for liver disease 
and do not allow easy discrimination of  intermediate 
stages of  fibrosis[95]. Score panels based on combined 
blood test data are also of  limited utility in differentiating 
the stages of  fibrosis. Biomarkers detect cirrhosis more 
readily than intermediate stages of  fibrosis[97,98]. However, 
the clinical utility of  markers in diagnosis of  liver cirrho-
sis requires further verification. 
Diagnostic performance
Several serum markers have been evaluated in terms of  
the ability to diagnose liver cirrhosis. These include the 
FibroTest, the APRI, the prothrombin index (PI), the 
AST/ALT ratio (the AAR), the Lok index, and the Gote-
borg University cirrhosis index (the GUCI)[99,100]. The Fi-
broTest and biopsy data performed similarly when used 
to diagnosis significant fibrosis in CHC patients[98,101-104]. 
One large study (of  913 CHC and 284 HBV patients) 
prospectively compared the most popular patented tests 
(the FibroTest, the Fibrometre, and the Hepacore) with 
a nonpatented test (the APRI); the AUROC values for 
cirrhosis ranged from 0.77 to 0.86 and no significant 
among-test differences in scores were evident[105]. Al-
though nonpatented tests such as the Forns index, the 
FIB-4, and the APRI may lack the performance of  the 
patented tests, the former tests are inexpensive, easy to 
perform, and widely available. However, few serum bio-
markers have been evaluated in terms of  the ability to 
define the stage of  liver cirrhosis in CHB patients. The 
results of  studies on CHC patients cannot be directly 
applied to CHB patients because CHB infection is associ-
ated with a specific type of  pathogenesis. Thus, dedicated 
validation of  marker utility in CHB patients is required. 
The FibroTest has been studied extensively over the 
last 5 years and is currently the best-understood serum 
marker panel used to detect fibrosis[106]. Application of  
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the FibroTest to CHB patients was associated with AU-
ROCs of  0.77-0.78 for detection of  significant fibrosis 
and cirrhosis, with 85.0% sensitivity and 52.0% specific-
ity[107,108].
The APRI is a simple test that combines AST level 
with platelet count to predict the occurrence of  significant 
fibrosis and cirrhosis in CHC patients. Venkatesh et al[92] 
showed that serum AST levels differed significantly be-
tween patients with low-grade and advanced fibrosis, but 
ALT levels did not. The APRI was helpful for discrimi-
nating CHB patients with advanced fibrosis from those 
with mild-to-moderate conditions. When the APRI cut-
off  was set at 0.5 for CHB patients, the AUROC for pre-
diction of  significant fibrosis was 0.673[109] and the PPV 
and NPV 30% and 87%, respectively. In other words, the 
APRI can reliably be used to exclude the presence of  sig-
nificant fibrosis. 
Hui et al[109] developed a predictive model based on 
body mass index (BMI) and the data of  three routine 
laboratory tests, which had an AUROC of  0.79 when 
used to assess the fibrosis stage of  CHB patients. The 
laboratory data were bilirubin, albumin, platelet, and ALP 
levels. The PPV was 38% when a cutoff  of  0.15 was ap-
plied and 53% when the cutoff  was 0.5. The results sug-
gest that the model should be used primarily to identify 
patients lacking significant fibrosis. 
Sebastiani et al[110] reported that sequential use of  
the APRI, the FibroTest, and liver biopsy data, greatly 
improved diagnostic performance compared to use of  
a single non-invasive test in CHB patients. The sequen-
tial combination was developed to detect cirrhosis in 
HBV patients. The need for liver biopsy was reduced by 
50%-80%. All of  the FibroTest, the APRI, the AAR, and 
the GUCI were only 77.5%-86.1% accurate in terms of  
cirrhosis detection when used individually. The FibroTest 
showed the best PPV, NPV, and AUROC for cirrhosis 
detection (90%, 87.1%, and 0.76, respectively). However, 
the sequential combination afforded excellent accuracy 
(100%) in terms of  detection. Stepwise combination al-
gorithms featuring the APRI, the FibroTest, and biopsy, 
afforded excellent performance (0.95 AUROC and 98.3% 
NPV for cirrhosis).
Montazeri et al[111] suggested that serum hyaluronate 
level might predict extensive liver fibrosis and inflamma-
tion in CHB patients. Zhang et al[112] suggested that use of  
the APRI test in combination with hyaluronic acid (HA) 
measurement could serve to detect moderate-to-severe 
fibrosis in CHB patients. When the APRI was used alone 
to this end, the sensitivity, specificity, PPV, and NPV were 
44.7%, 84.3%, 41.3%, and 84.7%, respectively. The diag-
nostic performance of  the APRI was low in terms of  dis-
crimination of  fibrosis stages in such patients. However, 
when an APRI score of  ≥ 1.5 was used in combination 
with an HA cutoff  of  > 300 ng/mL, moderate-to-severe 
fibrosis was accurately predicted in CHB patients (98.9% 
of  specificity and 93.7% of  PPV). 
Lebensztejn et al[113] reported that the AUROC of  
combined hyaluronan and laminin measurements was 
0.84. Zeng et al[114] developed a non-invasive combination 
model including age and measurements of  serum alpha-
2-macroglobulin, hyaluronan, and γ-glutamyl transpepti-
dase. The AUROCs were 0.77-0.84. The expected rate of  
misdiagnosis was around 20%, similar to that reported in 
hepatitis C patients. However, it may be inappropriate to 
apply the test in real clinical settings. Recently, “proteome” 
technology has been used to study liver fibrosis. A total 
of  30 features predictive of  significant fibrosis and cir-
rhosis were identified in 46 CHB patients. The AUROCs 
were high, being 0.906 and 0.921 for detection of  ad-
vanced fibrosis and cirrhosis, respectively[115]. However, 
the method is rather complicated and may not be appli-
cable to large-scale testing. 
A meta-analysis[116] of  data from 30 studies using the 
FibroTest and biopsy (3501 CHC and 1457 CHB pa-
tients) found that the mean standardized AUROC for di-
agnosis of  significant fibrosis was 0.84, and did not differ 
significantly between patients with CHC (0.85) and CHB 
(0.80). 
Advantages and disadvantages
The inter-laboratory reproducibilities of  the FibroMeter, 
FibroTest, and APRI tests, and combinations thereof, 
are excellent[117]. The APRI test is inexpensive and widely 
available (being nonpatented). However, these tests per-
form less well than does TE in terms of  cirrhosis diagno-
sis. Also, test results are not immediately available[95]. The 
tests are not specific for liver disease and do not discrimi-
nate among the intermediate stages of  fibrosis. Test re-
sults can be influenced by comorbidities, and critical data 
interpretation is required. False-positive FibroTest and 
Hepascore results are yielded by patients with Gilbert’s 
syndrome or hemolysis, because such patients exhibit hy-
perbilirubinemia[118]. Similarly, acute hepatitis can produce 
false-positive results in the APRI, Forns index, FIB-4, or 
Fibrometer tests.
DIAGNOSIS OF DECOMPENSATED 
CIRRHOSIS
Recently, noninvasive ultrasound- and MRI-based elas-
tographic techniques have allowed the relationships be-
tween liver or spleen stiffness and portal pressure to be 
explored. Use of  TE revealed a statistically significant 
association of  these parameters with the hepatic venous 
pressure gradient of  CHC patients[119,120], and a correla-
tion with the grade of  esophageal varices was evident[121]. 
Talwalkar et al[122] used MRE to show that splenomegaly, 
mean spleen stiffness, and serum platelet count were 
potentially associated with the presence of  esophageal 
varices. Neither the mean liver stiffness value nor the 
mean spleen volume was significantly associated with the 
presence of  esophageal varices. A cutoff  spleen stiffness 
value of  over 10.5 kPa identified all cirrhotic patients 
with esophageal varices.
Ye et al[123] reported that the liver stiffness cutoff  value 
of  ARFI was 1.88 m/s for diagnosis of  liver cirrhosis in 
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CHB patients (AUROC = 0.97; sensitivity, 95.7%; speci-
ficity, 91.8). Interestingly, spleen stiffness values were also 
determined in the cited study, to aid in diagnosis of  cir-
rhosis and esophageal varices. The spleen stiffness cut-
off  value was 2.72 m/s for diagnosis of  liver cirrhosis 
(AUROC = 0.96; sensitivity, 88.4%; specificity, 93.2%). 
The optimal spleen stiffness cutoff  predicting varices was 
3.16 m/s (AUROC = 0.83). In this report, portal hyper-
tensions could not be graded according to liver stiffness, 
but a significant linear correlation was evident between 
spleen stiffness and varices grade.
COMPARISONS OF MODALITIES USED 
TO DIAGNOSE CIRRHOSIS
TE and ARFI
Lupsor et al[66] found that both ARFI and TE data were 
strongly correlated with the stage of  fibrosis, and TE was 
superior when used to predict early-stage disease in pa-
tients with chronic hepatitis C. However, Ebinuma et al[65] 
found that the diagnostic powers of  the two techniques 
were almost identical. Neither mode detected low-grade 
fibrosis effectively, but diagnostic capacities rose as the 
stage of  fibrosis advanced. 
ARFI and TE were compared in a meta-analysis 
of  eight studies involving 518 patients. TE afforded a 
slightly higher diagnostic accuracy for cirrhosis (mean 
AUROC difference: 0.04)[124]. The mean AUROC of  all 
published studies on the use of  ARFI to detect cirrhosis 
in CHB patients was 0.90. However, most studies had 
small sample numbers and the study populations were 
heterogeneous. 
Friedrich-Rust et al[69] found that ARFI and TE per-
formed similarly when used to diagnose liver fibrosis 
in CHB patients. ARFI afforded excellent performance 
when used to diagnose advanced fibrosis, but differentia-
tion of  mild fibrosis was in need of  improvement. When 
a low cutoff  of  1.03 m/s was used to exclude significant 
fibrosis, and a high cutoff  of  1.39 m/s to confirm sig-
nificant fibrosis, 38% of  patients were correctly classified 
using ARFI. 
Cassinotto et al[55] compared the use of  ARFI, TE 
with the M and XL probes, and the FibroTest, in evalua-
tion of  321 patients (39 with HBV infections). In terms 
of  cirrhosis diagnosis, no significant difference was evi-
dent between ARFI elastography and TE with the M or 
XL probes. However, the diagnostic performance of  TE 
was significantly better than that of  the FibroTest.
Comparison of TE and MRE
In a comparative study, MRE was superior to both TE 
and APRI when used to assess liver fibrosis, affording 
accuracies of  over 98% in diagnosis of  all categories of  
fibrosis[89]. The AUROC of  MRE was 0.998 for diagno-
sis of  liver cirrhosis and the technical success rate was 
higher than that associated with ultrasound elastography 
(AUROC = 0.930), APRI (AUROC = 0.820), and a com-
bination of  TE with APRI (AUROC = 0.944).
Comparison of RTE and other elastographic modalities 
Colombo et al[125] compared the utility of  TE, RTE, and 
ARFI in diagnosis of  liver fibrosis. TE and ARFI exhib-
ited high diagnostic accuracies (AUROCs 0.9) when used 
to diagnose cirrhosis. All three methods afforded fair 
(AUROC = 0.7) to good (AUROC = 0.8) diagnostic ac-
curacy when used to diagnose all fibrosis (F1-4 Metavir 
grades) and significant fibrosis (F2-4 Metavir grades). Of  
the various modalities, TE exhibited the best diagnostic 
performance (AUROCs of  0.878 for fibrosis and 0.897 
for significant fibrosis, respectively). TE and ARFI were 
highly accurate when used to diagnose cirrhosis. 
Friedrich-Rust et al[79] found that the AUROCs for 
diagnosis of  significant fibrosis and cirrhosis using TE 
and RTE were 0.84 vs 0.69, and 0.97 vs 0.65, respectively. 
RTE was less accurate than TE when used to predict 
liver fibrosis. However, upon direct comparison of  TE, 
RTE, and ARFI in 74 Korean patients, the cut-off  val-
ues for diagnosis of  cirrhosis were 8.60 kPa (AUROC 
= 0.786; sensitivity, 81.0%; specificity, 64.2%); 1.39 m/s 
(AUROC = 0.807; sensitivity, 90.5%; specificity, 66.0%); 
and 2.79 (AUROC = 0.767; sensitivity, 81.0%; specificity, 
64.2%), respectively[126]. TE and ARFI, rather than RTE, 
are the best modalities for non-invasive assessment of  
liver fibrosis. However, all three methods reliably predict 
cirrhosis.
Comparison of elastography and serum biomarker 
measurements
In terms of  detection of  cirrhosis, AUROC analysis 
indicated that the APRI test was superior to the elastic 
strain ratio determined using real-time elastography, and 
the Forns index[84]. This suggests that the APRI should 
be used to diagnose cirrhosis in preference to calculation 
of  the elastic strain ratio. When the AUROCs of  spleen 
stiffness measurement and APRI were compared, the 
overall diagnostic performance of  the former test in pre-
diction of  liver fibrosis stages was superior to that of  the 
APRI[68]. The diagnostic accuracy of  the FibroTest was 
comparable to those of  elastographic methods. APRI 
scoring has been shown to be inferior to FibroTest- and 
TE-based evaluations[127,128].
Other methods for diagnosis of liver cirrhosis
Hu et al[129] measured newly maximal accumulative respi-
ration strain (MARS) values obtained from hepatic tissue 
image analysis of  CHB patients. Each value represents 
the average strain of  hepatic tissue in the ROI at different 
stages of  the respiratory cycle. The MARS values were 
correlated with fibrotic stage. The diagnostic accuracy 
rate for cirrhosis had an AUROC of  0.75. However, the 
performance of  MARS was inferior to that of  TE.
COMBINATION OF LSM WITH OTHER 
MODELS OF FIBROSIS PREDICTION 
The use of  combination models has been proposed to 
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increase the diagnostic performance of  tests for liver 
cirrhosis, although elastography alone accurately pre-
dicts histological cirrhosis. The combined use of  the 
Enhanced Liver Fibrosis (ELF) test with either ARFI or 
TE in patients with multi-origin cirrhosis increased the 
diagnostic accuracy of  liver cirrhosis[130]. The PPV and 
NPV of  ARFI-plus-ELF were 73% and 100%, and those 
of  TE-plus-ELF 64% and 100%, respectively. 
The ultimate validation of  liver fibrosis as a marker 
of  liver injury is the prognostic value thereof  in terms of  
morbidity and mortality. In recent studies on non-CHB 
patients, the TE test and measures of  serum fibrosis 
markers were prognostically more valuable than liver bi-
opsy data[131-133]. However, long-term follow-up studies on 
ARFI are required. 
Chung et al[126] explored the efficacies of  combina-
tions of  LSM modalities (TE, ARFI, and RTE) with 
platelet count in terms of  increasing the diagnostic power 
for liver disease of  varying etiology. Cutoff  ratios of  
LSM/(platelet count) used to predict cirrhosis were no 
more effective than the LSM data alone. However, the 
ratios predicted significant fibrosis (grade ≥ F2) more ef-
fectively than did LSM data alone. 
The diagnostic performance of  TE in CHB patients 
can be improved by combining test data with those of  
fibrosis serum marker levels derived using the APRI, 
Fib-4, Fibrometer and FibroTest[134-136]. Wong et al[137] re-
ported that agreement between a high LSM and a high 
Forns index value improved diagnostic specificity (from 
99% to 100% and from 87% to 98% in training and vali-
dation cohorts, respectively). Kim et al[138] derived optimal 
predictive threshold values of  the LSM/spleen diameter 
to platelet ratio index (LSPI; LSM × spleen diameter/
platelet count) for detection of  cirrhosis in terms of  ALT 
level. The AUROC was 0.956, thus slightly higher than 
the AUROC of  0.919 afforded by use of  TE data alone. 
When used to diagnose cirrhosis in patients with normal 
ALT levels, use of  an LSPI predictive threshold value of  
38 was associated with 98.0% sensitivity and 69.2% speci-
ficity, whereas a threshold value of  62 was associated 
with 85.9% sensitivity and 93.8% specificity. Similarly, in a 
high-level ALT group, an LSPI predictive threshold value 
of  42 was associated with 96.3% sensitivity and 67.4% 
specificity, whereas a threshold of  94 was associated with 
67.5% sensitivity and 97.7% specificity. 
Kim et al[46] found that optimal LSM cutoff  values var-
ied with ALT level, and use of  an index (a ratio) combin-
ing data on age, spleen size, and platelet level, enhanced 
Table 1  Diagnostic performance of non-invasive diagnostic methods in predicting cirrhosis with chronic hepatitis B
Ref. Year Modality Patients (n ) Cut-offs ≥ F4 Standard reference AUROC Se Sp Accuracy PPV NPV
Myers et al[107] 2003 Biomarkers 209 0.21 Biopsy 0.780   85.0%   52.0% -   43.0   92.0
0.41   54.0%   80.0% -   53.0   81.0
0.81   18.0%   99.0% -   92.0   75.0
Hui et al[109] 2005 Biomarkers 235   > 0.151 Biopsy 0.791   88.0%   50.0% 93.0   38.0   92.0
> 0.51 0.791   37.0%   88.0% -   53.0   81.0
Zeng et al[114] 2005 Biomarkers 200 > 3.01 Biopsy 0.770   94.8%   44.1% -   70.1   86.1
> 8.71 0.770   35.3%   95.2% -   91.1   51.6
Marcellin et al[20] 2009 TE 173 18.2 kPa2 Biopsy 0.930   57.0%   97.0% 94.0   67.0   96.0
11 kPa2 Biopsy 0.930   93.0%   87.0% 38.0   38.0   99.0
Chan et al[19] 2009 TE 161 13.4 kPa2 Biopsy 0.930   75.0%   93.0% 89.0   78.0   92.0
12 kPa3   79.0%   92.0% -   76.0   93.0
Kim et al[18] 2009 TE   91 10.3 kPa Biopsy 0.803   59.0%   78.0% -   68.0   72.0
Kim et al[52] 2010 TE 104 10.1 kPa Biopsy 0.849   86.7%   88.1% -   87.5   77.1
TE   52 15.5 kPa 0.867   66.7% 100.0% - 100.0   72.9
Kim et al[138] 2010 LSPI4 330 385 Biopsy 0.956   98.0%   69.2% -   82.9   95.7
625   85.9%   93.8% -   95.5   81.3
426   96.3%   67.4% -   73.3   95.1
946   67.5%   97.7% -   96.4   76.4
Hu et al[129] 2010 MARS   28 20.32% Biopsy 0.750 100.0% - - - -
Ye et al[123] 2011 ARFI 264 1.88 m/s Biopsy 0.970   95.7%   91.8%  - - -
Spleen ARFI 2.72 m/s 0.960   88.4%   93.2% - - -
Xie et al[84] 2012 RTE7   71 -0.6 Biopsy 0.797   50.0%   96.7%  -   71.4   92.2
APRI   71 Biopsy 0.930 - - - - -
Wang et al[85] 2012 RTE   75 90.31 Biopsy 0.660   71.4%   80.0% -   93.8   40.0
APRI   75 Biopsy 0.930 - -  - - -
Cassinotto et al[55] 2013 TE8 285 14.1 kPa Biopsy 0.910   77.0%   92.0% 89.0   74.0   93.0
TE9 254 10.1 kPa Biopsy 0.880   85.0%   82.0% 82.0   76.0   96.0
Friedrich-Rust et al[69] 2013 ARFI   92 Biopsy 0.970 - - - - -
TE   92 Biopsy 0.930 - - - - -
Venkatesh et al[92] 2013 MRE   64 4.33 kPa Biopsy 0.980 100.0%   95.2%  -   91.3 100.0
1Cut-off value for significant fibrosis; 2Cut-off value with maximum of diagnosis accuracy; 3Cut off value with a maximum sum of sensitivity and specificity; 
4Liver stiffness measurement × spleen diameter/platelet count; 5Cut-off value with normal alanine aminotransferase (ALT); 6Cut-off value with high ALT; 
7Elastic strand ratio; 8M probe; 9XL probe. LSPI: Liver stiffness measurement - spleen diameter to platelet ratio index; TE: Transient elastography; ARFI: 
Acoustic radiation force impulse imaging; RTE: Real-time elastography; MRE: Magnetic resonance elastography; MARS: Maximal accumulative respiration 
strain; Se: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; AUROC: Area under the receiver operating characteristic.
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LSM performance when used to diagnose cirrhosis in 
CHB patients (AUROCs = 0.917 in patients with ALT ≤ 
upper ULN; 0.909 in those with ALT ≤ 2 × ULN; and 
0.894 in all patients). 
Evaluation of  hepatitis B patients using elastography 
increased the accuracy of  these measures when used to 
diagnose cirrhosis. Increasing acceptance of  the utility of  
combination modalities is expected to reduce the require-
ment for liver biopsy. The combination methods enhance 
diagnostic accuracy and reduce the number of  liver biop-
sies needed to evaluate cirrhotic CHB patients. An opti-
mal choice of  diagnostic modality requires the conduct 
of  large-scale validation studies in a variety of  patient 
populations. Also, the cost-effectiveness of  combination 
models requires future attention.
CONCLUSION
The last decade has seen significant progress in develop-
ment of  noninvasive liver disease assessment in CHB 
patients (Table 1). It has become accepted that liver bi-
opsy has limitations when used to diagnose cirrhosis. TE, 
ARFI, RTE, and MRE are valuable for early diagnosis 
of  cirrhosis in CHB patients because the AUROC values 
associated with use of  these techniques are in excess of  
0.8[139]. 
Routine use of  TE in management of  hepatitis 
C patients has significantly reduced the need for liver 
biopsy[140], but reliable detection of  mild fibrosis and 
accurate differentiation of  fibrotic stages remain prob-
lematic[141-143]. In addition, accurate measurements may be 
difficult to obtain from obese patients, those with ascites, 
and those exhibiting severe hepatic atrophy. Acoustic 
radiation force impulse imaging is a novel form of  ultra-
sound providing in vivo information on the local mechani-
cal properties of  tissue[144,145]. However, ARFI cannot 
be used to evaluate patients who are obese or cirrhotic 
patients with very stiff  tissue because imaging results 
are automatically rejected if  detection of  low-frequency 
acoustic wave propagation is inadequate[63]. RTE does not 
have such limitations and can be used to image almost all 
patients, including those who cannot be assessed by TE 
or ARFI. MRE was more accurate than either ultrasound-
based elastography or measurement of  serum markers of  
fibrosis[88,89,93]. However, most previous studies on RTE 
and MRE included patients with chronic liver disease of  
various etiologies. RTE and MRE should be validated in 
CHB cohorts (with macronodular cirrhosis) in particular. 
TE is the most widely used method for diagnosis of  
cirrhosis in CHB patients, but ARFI and MRE may be 
equally valuable. Novel techniques including supersonic 
shear imaging[146,147] or measurement of  spleen stiff-
ness[148] may also be valuable in diagnosis of  liver cir-
rhosis. A combination of  elastography and biomarker 
measurements may improve diagnostic performance 
during surveillance of  CHB patients for development of  
liver cirrhosis. However, clinical benefit must be weighed 
against cost when a combined approach is planned. 
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